Clinical Trial Update: To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for FB-1603 in hepatocellular carcinoma patients undergoing transarterial chemoembolization (Phase 1/Phase 2; recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• FB-1603

Snippet

Sponsor: Febico Biomedical Corp. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING